Immunosuppression in Liver Transplantation: State of the Art and Future Perspectives

Author(s): Geir I. Nedredal*, Rafael V. Picon, Marcio F. Chedid, Aksel Foss

Journal Name: Current Pharmaceutical Design

Volume 26 , Issue 28 , 2020


Become EABM
Become Reviewer
Call for Editor

Abstract:

Background: Novel drugs and combinations for immunosuppression (IS) after liver transplantation is one main reason for improved graft and patient survival seen in the last decades. The backbone of IS is still steroids and calcineurin inhibitors, although novel drugs are being introduced, such as the mammalian target of rapamycin inhibitors (mTOR inhibitor). The challenge today, along with increased patient survival, is the adverse effects of long-term use of immunosuppressive drugs, mainly nephrotoxicity and other serious adverse effects.

Concepts: The ultimate outcome after liver transplantation would be achieving tolerance, a state where all IS can be withdrawn. In the meantime, different approaches to reduce and withdraw IS have been tested out in different clinical trials with the aim to reduce the adverse effects of steroids and calcineurin inhibitors. This has formed the basis of today’s clinical practice. The different combinations of immunosuppressive drugs have included mTOR inhibitor such as everolimus and different induction drugs such as anti-interleukin 2 receptor antibodies. Regarding induction drugs, lymphocyte depleting (alemtuzumab and ATG) and non-depleting agents, such as basiliximab, have shown advantageous effects.

Summary: Alongside steroid and calcineurin inhibitors reduction or elimination, current strategies for post-liver transplantation immunosuppression explore combinations of novel agents. The gauge (or yardstick) here is the fine balance between the adverse effects of IS drugs and the risk of rejection. Long-term maintenance IS regimens, development of tolerance and antibody-mediated rejection are also discussed in this review.

Keywords: Liver transplantation, immunosuppression, immunomodulation, calcineurin Inhibitors, glucocorticoids, transplantation tolerance, thymoglobulin, alemtuzumab.

[1]
Starzl TE, Groth CG, Brettschneider L, et al. Orthotopic homotransplantation of the human liver. Ann Surg 1968; 168(3): 392-415.
[http://dx.doi.org/10.1097/00000658-196809000-00009] [PMID: 4877589]
[2]
Borel JF, Feurer C, Gubler HU, Stähelin H. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 1976; 6(4): 468-75.
[http://dx.doi.org/10.1007/BF01973261] [PMID: 8969]
[3]
Calne RY, White DJ, Evans DB, et al. Cyclosporin A in cadaveric organ transplantation. Br Med J (Clin Res Ed) 1981; 282(6268): 934-6.
[http://dx.doi.org/10.1136/bmj.282.6268.934] [PMID: 6781658]
[4]
Wiesner RH, Fung JJ. Present state of immunosuppressive therapy in liver transplant recipients. Liver Transpl 2011; 17(Suppl. 3): S1-9.
[http://dx.doi.org/10.1002/lt.22410] [PMID: 21850697]
[5]
Taner T, Stegall MD, Heimbach JK. Antibody-mediated rejection in liver transplantation: current controversies and future directions. Liver Transpl 2014; 20(5): 514-27.
[http://dx.doi.org/10.1002/lt.23826] [PMID: 24470340]
[6]
Zeyda M, Geyeregger R, Poglitsch M, et al. Impairment of T cell interactions with antigen-presenting cells by immunosuppressive drugs reveals involvement of calcineurin and NF-kappaB in immunological synapse formation. J Leukoc Biol 2007; 81(1): 319-27.
[http://dx.doi.org/10.1189/jlb.0606378] [PMID: 17038582]
[7]
Larsen CP, Pearson TC, Adams AB, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant 2005; 5(3): 443-53.
[http://dx.doi.org/10.1111/j.1600-6143.2005.00749.x] [PMID: 15707398]
[8]
Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995; 270(5234): 286-90.
[http://dx.doi.org/10.1126/science.270.5234.286] [PMID: 7569976]
[9]
Hu H, Djuretic I, Sundrud MS, Rao A. Transcriptional partners in regulatory T cells: Foxp3, Runx and NFAT. Trends Immunol 2007; 28(8): 329-32.
[http://dx.doi.org/10.1016/j.it.2007.06.006] [PMID: 17618833]
[10]
Wells AD. Cell-cycle regulation of T-cell responses--novel approaches to the control of alloimmunity. Immunol Rev 2003; 196: 25-36.
[http://dx.doi.org/10.1046/j.1600-065X.2003.00080.x] [PMID: 14617195]
[11]
Stegall MD, Dean PG, Gloor J. Mechanisms of alloantibody production in sensitized renal allograft recipients. Am J Transplant 2009; 9(5): 998-1005.
[http://dx.doi.org/10.1111/j.1600-6143.2009.02612.x] [PMID: 19422329]
[12]
Stegall MD, Raghavaiah S, Gloor JM. The (re)emergence of B cells in organ transplantation. Curr Opin Organ Transplant 2010; 15(4): 451-5.
[http://dx.doi.org/10.1097/MOT.0b013e32833b9c11] [PMID: 20613525]
[13]
Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 1995; 270(5234): 283-6.
[http://dx.doi.org/10.1126/science.270.5234.283] [PMID: 7569975]
[14]
Klintmalm GB, Feng S, Lake JR, et al. Belatacept-based immunosuppression in de novo liver transplant recipients: 1-year experience from a phase II randomized study. Am J Transplant 2014; 14(8): 1817-27.
[http://dx.doi.org/10.1111/ajt.12810] [PMID: 25041339]
[15]
Boelaars-van Haperen MJAM, Baan CC, van Riemsdijk IC, IJzermans JNM, Weimar W. Treatment with the chimeric anti-IL-2Ralpha basiliximab affects both the IL-2 and IL-15 signalling pathways after clinical kidney transplantation. Transplant Proc 2001; 33(1-2): 1007-8.
[http://dx.doi.org/10.1016/S0041-1345(00)02306-X] [PMID: 11267166]
[16]
Vilar E, Perez-Garcia J, Tabernero J. Pushing the envelope in the mTOR pathway: the second generation of inhibitors. Mol Cancer Ther 2011; 10(3): 395-403.
[http://dx.doi.org/10.1158/1535-7163.MCT-10-0905] [PMID: 21216931]
[17]
Rostaing L, Saliba F, Calmus Y, Dharancy S, Boillot O. Review article: use of induction therapy in liver transplantation. Transplant Rev (Orlando) 2012; 26(4): 246-60.
[http://dx.doi.org/10.1016/j.trre.2012.06.002] [PMID: 22863028]
[18]
Toso C, Merani S, Bigam DL, Shapiro AMJ, Kneteman NM. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 2010; 51(4): 1237-43.
[http://dx.doi.org/10.1002/hep.23437] [PMID: 20187107]
[19]
Montenovo MI, Jalikis FG, Li M, et al. Superior patient and graft survival in adult liver transplant with rabbit antithymocyte globulin induction: experience with 595 patients. Exp Clin Transplant 2017; 15(4): 425-31.
[http://dx.doi.org/10.6002/ect.2015.0350] [PMID: 27309029]
[20]
Penninga L, Wettergren A, Wilson CH, Chan A-W, Steinbrüchel DA, Gluud C. Antibody induction versus placebo, no induction, or another type of antibody induction for liver transplant recipients. Cochrane Database Syst Rev 2014; (6): CD010253
[http://dx.doi.org/10.1002/14651858.CD010253.pub2] [PMID: 24901467]
[21]
Penninga L, Wettergren A, Wilson CH, Chan AW, Steinbrüchel DA, Gluud C. Antibody induction versus corticosteroid induction for liver transplant recipients. Cochrane Database Syst Rev 2014; (5): CD010252
[http://dx.doi.org/10.1002/14651858.CD010252.pub2] [PMID: 24880007]
[22]
Eason JD, Nair S, Cohen AJ, Blazek JL, Loss GE Jr. Steroid-free liver transplantation using rabbit antithymocyte globulin and early tacrolimus monotherapy. Transplantation 2003; 75(8): 1396-9.
[http://dx.doi.org/10.1097/01.TP.0000062834.30922.FE] [PMID: 12717237]
[23]
Hotta R, Ohira M, Matsuura T, et al. CD52-negative NK cells are abundant in the liver and less susceptible to alemtuzumab treatment. PLoS One 2016; 11(8) e0161618
[http://dx.doi.org/10.1371/journal.pone.0161618] [PMID: 27560943]
[24]
Starzl TE, Groth CG, Brettschneider L, et al. Extended survival in 3 cases of orthotopic homotransplantation of the human liver. Surgery 1968; 63(4): 549-63.
[http://dx.doi.org/10.1097/00007890-196810000-00022] [PMID: 4171413]
[25]
Starzl TE, Klintmalm GB, Porter KA, Iwatsuki S, Schröter GP. Liver transplantation with use of cyclosporin a and prednisone. N Engl J Med 1981; 305(5): 266-9.
[http://dx.doi.org/10.1056/NEJM198107303050507] [PMID: 7017414]
[26]
Starzl TE, Todo S, Fung J, Demetris AJ, Venkataramman R, Jain A. FK 506 for liver, kidney, and pancreas transplantation. Lancet 1989; 2(8670): 1000-4.
[http://dx.doi.org/10.1016/S0140-6736(89)91014-3] [PMID: 2478846]
[27]
U.S. Multicenter. FK506 Liver Study Group. A comparison of tacrolimus (FK 506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331(17): 1110-5.
[http://dx.doi.org/10.1056/NEJM199410273311702] [PMID: 7523946]
[28]
Matsuda S, Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacology 2000; 47(2-3): 119-25.
[http://dx.doi.org/10.1016/S0162-3109(00)00192-2] [PMID: 10878286]
[29]
Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. European FK506 Multicentre Liver Study Group. Lancet 1994; 344(8920): 423-8.
[http://dx.doi.org/10.1016/S0140-6736(94)91766-3] [PMID: 7520105]
[30]
Platz KP, Sollinger HW, Hullett DA, Eckhoff DE, Eugui EM, Allison AC. RS-61443--a new, potent immunosuppressive agent. Transplantation 1991; 51(1): 27-31.
[http://dx.doi.org/10.1097/00007890-199101000-00003] [PMID: 1987698]
[31]
Rodríguez-Perálvarez M, Guerrero-Misas M, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS. Maintenance immunosuppression for adults undergoing liver transplantation: a network meta-analysis. Cochrane Database Syst Rev 2017; 3CD011639
[http://dx.doi.org/10.1002/14651858.CD011639.pub2] [PMID: 28362060]
[32]
Eckhoff DE, McGuire BM, Frenette LR, Contreras JL, Hudson SL, Bynon JS. Tacrolimus (FK506) and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation. Transplantation 1998; 65(2): 180-7.
[http://dx.doi.org/10.1097/00007890-199801270-00006] [PMID: 9458011]
[33]
Watson CJE, Friend PJ, Jamieson NV, et al. Sirolimus: a potent new immunosuppressant for liver transplantation. Transplantation 1999; 67(4): 505-9.
[http://dx.doi.org/10.1097/00007890-199902270-00002] [PMID: 10071017]
[34]
Xu X, Ye L, Araki K, Ahmed R. mTOR, linking metabolism and immunity. Semin Immunol 2012; 24(6): 429-35.
[http://dx.doi.org/10.1016/j.smim.2012.12.005] [PMID: 23352227]
[35]
Vézina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo) 1975; 28(10): 721-6.
[http://dx.doi.org/10.7164/antibiotics.28.721] [PMID: 1102508]
[36]
Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 2003; 35(3)(Suppl.): 7S-14S.
[http://dx.doi.org/10.1016/S0041-1345(03)00211-2] [PMID: 12742462]
[37]
Price DJ, Grove JR, Calvo V, Avruch J, Bierer BE. Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase. Science 1992; 257(5072): 973-7.
[http://dx.doi.org/10.1126/science.1380182] [PMID: 1380182]
[38]
Massoud O, Wiesner RH. The use of sirolimus should be restricted in liver transplantation. J Hepatol 2012; 56(1): 288-90.
[http://dx.doi.org/10.1016/j.jhep.2011.06.012] [PMID: 21741926]
[39]
Pascual J. Everolimus in clinical practice--renal transplantation. Nephrol Dial Transplant 2006; 21(Suppl. 3): iii18-23.
[http://dx.doi.org/10.1093/ndt/gfl300] [PMID: 16815852]
[40]
Tedesco Silva H Jr, Cibrik D, Johnston T, et al. Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transplant 2010; 10(6): 1401-13.
[http://dx.doi.org/10.1111/j.1600-6143.2010.03129.x] [PMID: 20455882]
[41]
Nashan B. mTOR Inhibition and clinical transplantation: liver. Transplantation 2018; 102(2S)(Suppl. 1): S19-26.
[http://dx.doi.org/10.1097/TP.0000000000001690] [PMID: 28230639]
[42]
Chedid MF, Picon RV, Chedid AD. ALBI and PALBI: Novel scores for outcome prediction of cirrhotic outpatients awaiting liver transplantation. Ann Hepatol 2018; 17(6): 906-7.
[http://dx.doi.org/10.5604/01.3001.0012.7190] [PMID: 30600306]
[43]
Chedid MF. Nonalcoholic Steatohepatitis: The second leading indication for liver transplantation in the USA. Dig Dis Sci 2017; 62(10): 2621-2.
[http://dx.doi.org/10.1007/s10620-017-4724-6] [PMID: 28840385]
[44]
Cholankeril G, Wong RJ, Hu M, et al. Liver transplantation for nonalcoholic steatohepatitis in the US: temporal trends and outcomes. Dig Dis Sci 2017; 62(10): 2915-22.
[http://dx.doi.org/10.1007/s10620-017-4684-x] [PMID: 28744836]
[45]
LaMattina JC, Mezrich JD, Fernandez LA, et al. Native kidney function following liver transplantation using calcineurin inhibitors: single-center analysis with 20 years of follow-up. Clin Transplant 2013; 27(2): 193-202.
[http://dx.doi.org/10.1111/ctr.12063] [PMID: 23294013]
[46]
Kim WR, Lake JR, Smith JM, et al. OPTN/SRTR 2016 annual data report: liver. Am J Transplant 2018; 18(Suppl. 1): 172-253.
[http://dx.doi.org/10.1111/ajt.14559] [PMID: 29292603]
[47]
Fairfield C, Penninga L, Powell J, Harrison EM, Wigmore SJ. Glucocorticosteroid-free versus glucocorticosteroid-containing immunosuppression for liver transplanted patients. Cochrane Database Syst Rev 2018; 4, CD007606
[http://dx.doi.org/10.1002/14651858.CD007606.pub4] [PMID: 29630730]
[48]
Fung J, Abu-Elmagd K, Jain A, et al. A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. Transplant Proc 1991; 23(6): 2977-83.
[PMID: 1721333]
[49]
Porayko MK, Textor SC, Krom RAF, et al. Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation. Mayo Clin Proc 1994; 69(2): 105-11.
[http://dx.doi.org/10.1016/S0025-6196(12)61034-9] [PMID: 7508536]
[50]
Muduma G, Saunders R, Odeyemi I, Pollock RF. Systematic review and meta-analysis of tacrolimus versus ciclosporin as primary immunosuppression after liver transplant. PLoS One 2016; 11(11)e0160421
[http://dx.doi.org/10.1371/journal.pone.0160421] [PMID: 27812112]
[51]
Kong Y, Wang D, Shang Y, et al. Calcineurin-inhibitor minimization in liver transplant patients with calcineurin-inhibitor-related renal dysfunction: a meta-analysis. PLoS One 2011; 6(9) e24387
[http://dx.doi.org/10.1371/journal.pone.0024387] [PMID: 21931704]
[52]
Penninga L, Wettergren A, Chan AW, Steinbrüchel DA, Gluud C. Calcineurin inhibitor minimisation versus continuation of calcineurin inhibitor treatment for liver transplant recipients. Cochrane Database Syst Rev 2012; (3): CD008852
[http://dx.doi.org/10.1002/14651858.CD008852.pub2] [PMID: 22419339]
[53]
Shaked A, DesMarais MR, Kopetskie H, et al. Outcomes of immunosuppression minimization and withdrawal early after liver transplantation. Am J Transplant 2018; 19: 1397-409.
[http://dx.doi.org/10.1111/ajt.15205] [PMID: 30506630]
[54]
Stegall MD, Wachs ME, Everson G, et al. Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus. Transplantation 1997; 64(12): 1755-60.
[http://dx.doi.org/10.1097/00007890-199712270-00023] [PMID: 9422416]
[55]
European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 1995; 345(8961): 1321-5.
[http://dx.doi.org/10.1016/S0140-6736(95)92534-1] [PMID: 7752752]
[56]
Sollinger HW US. Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 1995; 60(3): 225-32.
[http://dx.doi.org/10.1097/00007890-199508000-00003] [PMID: 7645033]
[57]
Klintmalm GB, Ascher NL, Busuttil RW, et al. RS-61443 for treatment-resistant human liver rejection. Transplant Proc 1993; 25(1 Pt 1): 697.
[PMID: 8438442]
[58]
Belli LS, de Carlis L, Rondinara G, et al. Early cyclosporine monotherapy in liver transplantation: a 5-year follow-up of a prospective, randomized trial. Hepatology 1998; 27(6): 1524-9.
[http://dx.doi.org/10.1002/hep.510270609] [PMID: 9620322]
[59]
Wiesner RH. A long-term comparison of tacrolimus (FK506) versus cyclosporine in liver transplantation: a report of the United States FK506 Study Group. Transplantation 1998; 66(4): 493-9.
[http://dx.doi.org/10.1097/00007890-199808270-00014] [PMID: 9734494]
[60]
Zervos XA, Weppler D, Fragulidis GP, et al. Comparison of tacrolimus with microemulsion cyclosporine as primary immunosuppression in hepatitis C patients after liver transplantation. Transplantation 1998; 65(8): 1044-6.
[http://dx.doi.org/10.1097/00007890-199804270-00006] [PMID: 9583863]
[61]
Fisher RA, Ham JM, Marcos A, et al. A prospective randomized trial of mycophenolate mofetil with neoral or tacrolimus after orthotopic liver transplantation. Transplantation 1998; 66(12): 1616-21.
[http://dx.doi.org/10.1097/00007890-199812270-00008] [PMID: 9884248]
[62]
Sterneck M, Fischer L, Gahlemann C, Gundlach M, Rogiers X, Broelsch C. Mycophenolate mofetil for prevention of liver allograft rejection: initial results of a controlled clinical trial. Ann Transplant 2000; 5(1): 43-6.
[PMID: 10850611]
[63]
Jain A, Kashyap R, Dodson F, et al. A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone and mycophenolate mofetil in primary adult liver transplantation: a single center report. Transplantation 2001; 72(6): 1091-7.
[http://dx.doi.org/10.1097/00007890-200109270-00019] [PMID: 11579306]
[64]
O’Grady JG, Burroughs A, Hardy P, Elbourne D, Truesdale A. UK and Republic of Ireland Liver Transplant Study Group. Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial. Lancet 2002; 360(9340): 1119-25.
[http://dx.doi.org/10.1016/S0140-6736(02)11196-2] [PMID: 12387959]
[65]
Greig P, Lilly L, Scudamore C, et al. Early steroid withdrawal after liver transplantation: the Canadian tacrolimus versus microemulsion cyclosporin A trial: 1-year follow-up. Liver Transpl 2003; 9(6): 587-95.
[http://dx.doi.org/10.1053/jlts.2003.50102] [PMID: 12783400]
[66]
Martin P, Busuttil RW, Goldstein RM, et al. Impact of tacrolimus versus cyclosporine in hepatitis C virus-infected liver transplant recipients on recurrent hepatitis: a prospective, randomized trial. Liver Transpl 2004; 10(10): 1258-62.
[http://dx.doi.org/10.1002/lt.20222] [PMID: 15376310]
[67]
Boudjema K, Camus C, Saliba F, et al. Reduced-dose tacrolimus with mycophenolate mofetil vs. standard-dose tacrolimus in liver transplantation: a randomized study. Am J Transplant 2011; 11(5): 965-76.
[http://dx.doi.org/10.1111/j.1600-6143.2011.03486.x] [PMID: 21466650]
[68]
Cholongitas E, Shusang V, Germani G, et al. Long-term follow-up of immunosuppressive monotherapy in liver transplantation: tacrolimus and microemulsified cyclosporin. Clin Transplant 2011; 25(4): 614-24.
[http://dx.doi.org/10.1111/j.1399-0012.2010.01321.x] [PMID: 20718824]
[69]
Pelletier SJ, Nadig SN, Lee DD, et al. A prospective, randomized trial of complete avoidance of steroids in liver transplantation with follow-up of over 7 years. HPB (Oxford) 2013; 15(4): 286-93.
[http://dx.doi.org/10.1111/j.1477-2574.2012.00576.x] [PMID: 23458449]
[70]
Manousou P, Cholongitas E, Samonakis D, et al. Reduced fibrosis in recurrent HCV with tacrolimus, azathioprine and steroids versus tacrolimus: randomised trial long term outcomes. Gut 2014; 63(6): 1005-13.
[http://dx.doi.org/10.1136/gutjnl-2013-305606] [PMID: 24131637]
[71]
Kwo PY. Direct acting antiviral therapy after liver transplantation. Curr Opin Gastroenterol 2016; 32(3): 152-8.
[http://dx.doi.org/10.1097/MOG.0000000000000266] [PMID: 27023161]
[72]
De Simone P, Metselaar HJ, Fischer L, et al. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial. Liver Transpl 2009; 15(10): 1262-9.
[http://dx.doi.org/10.1002/lt.21827] [PMID: 19790150]
[73]
Masetti M, Montalti R, Rompianesi G, et al. Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function. Am J Transplant 2010; 10(10): 2252-62.
[http://dx.doi.org/10.1111/j.1600-6143.2010.03128.x] [PMID: 20486905]
[74]
De Simone P, Nevens F, De Carlis L, et al. H2304 Study Group. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant 2012; 12(11): 3008-20.
[http://dx.doi.org/10.1111/j.1600-6143.2012.04212.x] [PMID: 22882750]
[75]
Asrani SK, Wiesner RH, Trotter JF, et al. De novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000-2003 phase II prospective randomized trial. Am J Transplant 2014; 14(2): 356-66.
[http://dx.doi.org/10.1111/ajt.12543] [PMID: 24456026]
[76]
Sterneck M, Kaiser GM, Heyne N, et al. Everolimus and early calcineurin inhibitor withdrawal: 3-year results from a randomized trial in liver transplantation. Am J Transplant 2014; 14(3): 701-10.
[http://dx.doi.org/10.1111/ajt.12615] [PMID: 24502384]
[77]
Sanchez W, Talwalkar JA, Gores GJ. Will all liver transplantation patients eventually die from cancer? J Hepatol 2006; 44(1): 13-8.
[http://dx.doi.org/10.1016/j.jhep.2005.10.007] [PMID: 16297490]
[78]
Rodríguez-Perálvarez M, De la Mata M, Burroughs AK. Liver transplantation: immunosuppression and oncology. Curr Opin Organ Transplant 2014; 19(3): 253-60.
[http://dx.doi.org/10.1097/MOT.0000000000000069] [PMID: 24685671]
[79]
Engels EA, Pfeiffer RM, Fraumeni JF Jr, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA 2011; 306(17): 1891-901.
[http://dx.doi.org/10.1001/jama.2011.1592] [PMID: 22045767]
[80]
Mazzaferro V, Llovet JM, Miceli R, et al. Metroticket Investigator Study Group. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10(1): 35-43.
[http://dx.doi.org/10.1016/S1470-2045(08)70284-5] [PMID: 19058754]
[81]
Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334(11): 693-9.
[http://dx.doi.org/10.1056/NEJM199603143341104] [PMID: 8594428]
[82]
Chedid MF, Kruel CRP, Pinto MA, et al. Hepatocellular carcinoma: diagnosis and operative management. Arq Bras Cir Dig 2017; 30(4): 272-8.
[http://dx.doi.org/10.1590/0102-6720201700040011] [PMID: 29340553]
[83]
Chagas AL, Felga GEG, Diniz MA, et al. Brazilian HCC Study Group. Hepatocellular carcinoma recurrence after liver transplantation in a Brazilian multicenter study: clinical profile and prognostic factors of survival. Eur J Gastroenterol Hepatol 2019; 31(9): 1148-56.
[http://dx.doi.org/10.1097/MEG.0000000000001448] [PMID: 31247632]
[84]
Chedid MF, Scaffaro LA, Chedid AD, et al. Transarterial embolization and percutaneous ethanol injection as an effective bridge therapy before liver transplantation for hepatitis c-related hepatocellular carcinoma. Gastroenterol Res Pract 2016; 2016, 9420274
[http://dx.doi.org/10.1155/2016/9420274] [PMID: 26819615]
[85]
Klintmalm GB, Saab S, Hong JC, Nashan B. The role of mammalian target of rapamycin inhibitors in the management of post-transplant malignancy. Clin Transplant 2014; 28(6): 635-48.
[http://dx.doi.org/10.1111/ctr.12357] [PMID: 24628264]
[86]
Geissler EK, Schnitzbauer AA, Zülke C, et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial. Transplantation 2016; 100(1): 116-25.
[http://dx.doi.org/10.1097/TP.0000000000000965] [PMID: 26555945]
[87]
Ethun CG, Lopez-Aguiar AG, Anderson DJ, et al. Transplantation versus resection for hilar cholangiocarcinoma: an argument for shifting treatment paradigms for resectable disease. Ann Surg 2018; 267(5): 797-805.
[http://dx.doi.org/10.1097/SLA.0000000000002574] [PMID: 29064885]
[88]
Rosen CB, Heimbach JK, Gores GJ. Liver transplantation for cholangiocarcinoma. Transpl Int 2010; 23(7): 692-7.
[http://dx.doi.org/10.1111/j.1432-2277.2010.01108.x] [PMID: 20497401]
[89]
Dueland S, Foss A, Solheim JM, Hagness M, Line P-D. Survival following liver transplantation for liver-only colorectal metastases compared with hepatocellular carcinoma. Br J Surg 2018; 105(6): 736-42.
[http://dx.doi.org/10.1002/bjs.10769] [PMID: 29532908]
[90]
Yao JC, Shah MH, Ito T, et al. RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364(6): 514-23.
[http://dx.doi.org/10.1056/NEJMoa1009290] [PMID: 21306238]
[91]
Nigri G, Petrucciani N, Debs T, et al. Treatment options for PNET liver metastases: a systematic review. World J Surg Oncol 2018; 16(1): 142.
[http://dx.doi.org/10.1186/s12957-018-1446-y] [PMID: 30007406]
[92]
Starzl TE, Zinkernagel RM. Transplantation tolerance from a historical perspective. Nat Rev Immunol 2001; 1(3): 233-9.
[http://dx.doi.org/10.1038/35105088] [PMID: 11905833]
[93]
Billingham RE, Brent L, Medawar PB. Actively acquired tolerance of foreign cells. Nature 1953; 172(4379): 603-6.
[http://dx.doi.org/10.1038/172603a0] [PMID: 13099277]
[94]
Feng S, Ekong UD, Lobritto SJ, et al. Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA 2012; 307(3): 283-93.
[http://dx.doi.org/10.1001/jama.2011.2014] [PMID: 22253395]
[95]
Levitsky J. Operational tolerance: past lessons and future prospects. Liver Transpl 2011; 17(3): 222-32.
[http://dx.doi.org/10.1002/lt.22265] [PMID: 21384504]
[96]
Chandrasekharan D, Issa F, Wood KJ. Achieving operational tolerance in transplantation: how can lessons from the clinic inform research directions? Transpl Int 2013; 26(6): 576-89.
[http://dx.doi.org/10.1111/tri.12081] [PMID: 23517251]
[97]
Porrett P, Shaked A. The failure of immunosuppression withdrawal: patient benefit is not detectable, inducible, or reproducible. Liver Transpl 2011; 17(Suppl. 3): S66-8.
[http://dx.doi.org/10.1002/lt.22377] [PMID: 21748844]
[98]
Demetris AJ, Lunz JG III, Randhawa P, Wu T, Nalesnik M, Thomson AW. Monitoring of human liver and kidney allograft tolerance: a tissue/histopathology perspective. Transpl Int 2009; 22(1): 120-41.
[http://dx.doi.org/10.1111/j.1432-2277.2008.00765.x] [PMID: 18980624]
[99]
Devlin J, Doherty D, Thomson L, et al. Defining the outcome of immunosuppression withdrawal after liver transplantation. Hepatology 1998; 27(4): 926-33.
[http://dx.doi.org/10.1002/hep.510270406] [PMID: 9537430]
[100]
Calne RY, Sells RA, Pena JR, et al. Induction of immunological tolerance by porcine liver allografts. Nature 1969; 223(5205): 472-6.
[http://dx.doi.org/10.1038/223472a0] [PMID: 4894426]
[101]
Calne R. Immunological tolerance: the liver effect. J Gastroenterol Hepatol 2002; 17(Suppl.): S488-90.
[http://dx.doi.org/10.1046/j.1440-1746.17.s4.15.x] [PMID: 12534783]
[102]
Gugenheim J, Le Thai B, Rouger P, et al. Relationship between the liver and lymphocytotoxic alloantibodies in inbred rats. Specific absorption by nonparenchymal liver cells. Transplantation 1988; 45(2): 474-8.
[http://dx.doi.org/10.1097/00007890-198802000-00046] [PMID: 3278442]
[103]
Pulford K, Souhami RL. The surface properties and antigen-presenting function of hepatic non-parenchymal cells. Clin Exp Immunol 1981; 46(3): 581-8.
[PMID: 6175463]
[104]
Nedredal GI, Elvevold K, Ytrebø LM, et al. Porcine liver sinusoidal endothelial cells contribute significantly to intrahepatic ammonia metabolism. Hepatology 2009; 50(3): 900-8.
[http://dx.doi.org/10.1002/hep.23076] [PMID: 19585612]
[105]
Løvdal T, Andersen E, Brech A, Berg T. Fc receptor mediated endocytosis of small soluble immunoglobulin G immune complexes in Kupffer and endothelial cells from rat liver. J Cell Sci 2000; 113(Pt 18): 3255-66.
[PMID: 10954423]
[106]
Olausson M, Mjörnstedt L, Nordén G, et al. Successful combined partial auxiliary liver and kidney transplantation in highly sensitized cross-match positive recipients. Am J Transplant 2007; 7(1): 130-6.
[http://dx.doi.org/10.1111/j.1600-6143.2006.01592.x] [PMID: 17227562]
[107]
Bradfield JW. Control of spillover. The importance of Kupffer-cell function in clinical medicine. Lancet 1974; 2(7885): 883-6.
[http://dx.doi.org/10.1016/S0140-6736(74)91213-6] [PMID: 4137592]
[108]
Lautenschlager I, Häyry P. Expression of the major histocompatibility complex antigens on different liver cellular components in rat and man. Scand J Immunol 1981; 14(4): 421-6.
[http://dx.doi.org/10.1111/j.1365-3083.1981.tb00582.x] [PMID: 7336172]
[109]
Michalopoulos GK. Liver regeneration. J Cell Physiol 2007; 213(2): 286-300.
[http://dx.doi.org/10.1002/jcp.21172] [PMID: 17559071]
[110]
Taylor AL, Gibbs P, Sudhindran S, et al. Monitoring systemic donor lymphocyte macrochimerism to aid the diagnosis of graft-versus-host disease after liver transplantation. Transplantation 2004; 77(3): 441-6.
[http://dx.doi.org/10.1097/01.TP.0000103721.29729.FE] [PMID: 14966423]
[111]
Zuber J, Sykes M. Mechanisms of mixed chimerism-based transplant tolerance. Trends Immunol 2017; 38(11): 829-43.
[http://dx.doi.org/10.1016/j.it.2017.07.008] [PMID: 28826941]
[112]
Alexander SI, Smith N, Hu M, et al. Chimerism and tolerance in a recipient of a deceased-donor liver transplant. N Engl J Med 2008; 358(4): 369-74.
[http://dx.doi.org/10.1056/NEJMoa0707255] [PMID: 18216357]
[113]
Kawai T, Cosimi AB, Spitzer TR, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008; 358(4): 353-61.
[http://dx.doi.org/10.1056/NEJMoa071074] [PMID: 18216355]
[114]
Karimi MH, Geramizadeh B, Malek-Hosseini SA. Tolerance induction in liver. Int J Organ Transplant Med 2015; 6(2): 45-54.
[PMID: 26082828]
[115]
Martínez-Llordella M, Puig-Pey I, Orlando G, et al. Multiparameter immune profiling of operational tolerance in liver transplantation. Am J Transplant 2007; 7(2): 309-19.
[http://dx.doi.org/10.1111/j.1600-6143.2006.01621.x] [PMID: 17241111]
[116]
Sarwal MM. Fingerprints of transplant tolerance suggest opportunities for immunosuppression minimization. Clin Biochem 2016; 49(4-5): 404-10.
[http://dx.doi.org/10.1016/j.clinbiochem.2016.01.007] [PMID: 26794635]
[117]
Bhat M, Mara K, Dierkhising R. Watt. Predictors of malignancies across solid organ transplantation. Am J Transplant 2017; 17.
[118]
Bhat M, Pasini E, Baciu C, Kurian S, Levitsky J. Decreased cancer susceptibility in tolerant liver transplant recipients: another benefit of tolerance? Am J Transplant 2019; 19.
[119]
OʼLeary JG, Samaniego M, Barrio MC, et al. The influence of immunosuppressive agents on the risk of de novo donor-specific hla antibody production in solid organ transplant recipients. Transplantation 2016; 100(1): 39-53.
[http://dx.doi.org/10.1097/TP.0000000000000869] [PMID: 26680372]
[120]
Vincenti F, Rostaing L, Grinyo J, et al. Belatacept and long-term outcomes in kidney transplantation. N Engl J Med 2016; 374(4): 333-43.
[http://dx.doi.org/10.1056/NEJMoa1506027] [PMID: 26816011]
[121]
Malvezzi P, Jouve T, Rostaing L. Costimulation blockade in kidney transplantation: an update. Transplantation 2016; 100(11): 2315-23.
[http://dx.doi.org/10.1097/TP.0000000000001344] [PMID: 27472094]
[122]
Cordoba F, Wieczorek G, Audet M, et al. A novel, blocking, Fc silent anti-CD40 monoclonal antibody prolongs nonhuman primate renal allograft survival in the absence of B cell depletion. Am J Transplant 2015; 15(11): 2825-36.
[http://dx.doi.org/10.1111/ajt.13377] [PMID: 26139432]
[123]
Vindigni SM, Surawicz CM. The gut microbiome: a clinically significant player in transplantation? Expert Rev Clin Immunol 2015; 11(7): 781-3.
[http://dx.doi.org/10.1586/1744666X.2015.1043894] [PMID: 26065325]
[124]
Doycheva I, Leise MD, Watt KD. The intestinal microbiome and the liver transplant recipient: what we know and what we need to know. Transplantation 2016; 100(1): 61-8.
[http://dx.doi.org/10.1097/TP.0000000000001008] [PMID: 26647107]
[125]
Jordan SC, Lorant T, Choi J, et al. IgG Endopeptidase in highly sensitized patients undergoing transplantation. N Engl J Med 2017; 377(5): 442-53.
[http://dx.doi.org/10.1056/NEJMoa1612567] [PMID: 28767349]
[126]
Fischer LJ, Klempnauer S, Beckebaum HJ, et al. A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation--PROTECT. Am J Transplant 12(7): 1855-65.
[127]
Nashan B, P. Schemmer, F. Braun, M. Dworak, P. Wimmer, and H. Schlitt. (2015) Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial. Trials 16: 118.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 26
ISSUE: 28
Year: 2020
Published on: 31 August, 2020
Page: [3389 - 3401]
Pages: 13
DOI: 10.2174/1381612826666200610183608
Price: $65

Article Metrics

PDF: 57
HTML: 7